文献速递重症综合管理与镇静镇痛

ICU谵妄持续时间与严重程度的生物标志物

Biomarkers of Delirium Duration and Delirium Severity in the ICU.
PubMed 文献 · Crit Care Med · 2020-01-01
一句话结论在ICU谵妄患者中,全身炎症及星形胶质细胞/胶质激活标志物(IL-6、IL-8、IL-10、TNF-α、CRP、S-100β)最高四分位水平与谵妄持续时间更长、严重程度更高及院内死亡相关。

研究为观察性研究,纳入3家印第安纳波利斯医院的321例重症谵妄患者,在谵妄发生时采集血生物标志物,分析其与谵妄/昏迷无天数、谵妄严重程度(CAM-ICU-7)及院内死亡率的关系。校正年龄、性别、APACHE II评分、Charlson合并症评分、脓毒症诊断及研究干预组后,IL-6、IL-8、IL-10、TNF-α、CRP和S-100β最高四分位水平与入组后1周和30天谵妄/昏迷无天数减少负相关;IL-6、IL-8、IL-10、TNF-α、CRP和S-100β最高四分位水平也与1周时谵妄严重程度相关。出院时IL-6、IL-8、IL-10仍与谵妄严重程度相关,而TNF-α、CRP、S-100β失去关联;IL-8和S-100β最高四分位水平还与院内死亡率升高相关。

要点

  • 在321例ICU谵妄患者中,IL-6、IL-8、IL-10、TNF-α、CRP和S-100β最高四分位水平与入组后1周和30天谵妄/昏迷无天数减少负相关。
  • IL-6、IL-8、IL-10、TNF-α、CRP和S-100β最高四分位水平与1周时谵妄严重程度(CAM-ICU-7评估)相关。
  • 出院时IL-6、IL-8、IL-10仍与谵妄严重程度相关,而TNF-α、CRP、S-100β失去关联。
  • IL-8和S-100β最高四分位水平与院内死亡率升高相关;IL-6、IL-10、TNF-α和IGF-1未发现与院内死亡率相关。
  • IGF-1最高四分位水平与1周和30天谵妄/昏迷无天数及两个时间点的谵妄严重程度均无关联。

适用人群与场景

  • 3家印第安纳波利斯医院收治的321例重症谵妄患者。

诊断标准与关键阈值

  • 谵妄评估采用ICU意识模糊评估法(CAM-ICU),谵妄/昏迷无天数采用Richmond躁动-镇静量表(RASS)/CAM-ICU评估。
  • 谵妄严重程度采用CAM-ICU-7评估。

研究设计与关键结果

  • 观察性研究,纳入3家印第安纳波利斯医院的321例重症谵妄患者,在谵妄发生时采集血生物标志物。
  • 校正年龄、性别、APACHE II评分、Charlson合并症评分、脓毒症诊断及研究干预组后,IL-6、IL-8、IL-10、TNF-α、CRP和S-100β最高四分位水平与入组后1周和30天谵妄/昏迷无天数减少负相关。
  • IL-6、IL-8、IL-10、TNF-α、CRP和S-100β最高四分位水平与1周时谵妄严重程度相关。
  • 出院时IL-6、IL-8、IL-10仍与谵妄严重程度相关,而TNF-α、CRP、S-100β失去关联。
  • IL-8和S-100β最高四分位水平与院内死亡率升高相关;IL-6、IL-10、TNF-α和IGF-1未发现与院内死亡率相关。
  • IGF-1最高四分位水平与1周和30天谵妄/昏迷无天数及两个时间点的谵妄严重程度均无关联。

证据类型、等级与局限

  • 证据类型:观察性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,全身炎症及星形胶质细胞/胶质激活生物标志物与谵妄持续时间更长、严重程度更高及院内死亡相关。
  • 作者认为,这些生物标志物在谵妄发生早期用于识别严重和迁延性谵妄及住院期间谵妄相关并发症高风险患者的效用,需在未來研究中探索。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Both delirium duration and delirium severity are associated with adverse patient outcomes. Serum biomarkers associated with delirium duration and delirium severity in ICU patients have not been reliably identified. We conducted our study to identify peripheral biomarkers representing systemic inflammation, impaired neuroprotection, and astrocyte activation associated with delirium duration, delirium severity, and in-hospital mortality.

DESIGN: Observational study.

SETTING: Three Indianapolis hospitals.

PATIENTS: Three-hundred twenty-one critically ill delirious patients.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: We analyzed the associations between biomarkers collected at delirium onset and delirium-/coma-free days assessed through Richmond Agitation-Sedation Scale/Confusion Assessment Method for the ICU, delirium severity assessed through Confusion Assessment Method for the ICU-7, and in-hospital mortality. After adjusting for age, gender, Acute Physiology and Chronic Health Evaluation II score, Charlson comorbidity score, sepsis diagnosis and study intervention group, interleukin-6, -8, and -10, tumor necrosis factor-α, C-reactive protein, and S-100β levels in quartile 4 were negatively associated with delirium-/coma-free days by 1 week and 30 days post enrollment. Insulin-like growth factor-1 levels in quartile 4 were not associated with delirium-/coma-free days at both time points. Interleukin-6, -8, and -10, tumor necrosis factor-α, C-reactive protein, and S-100β levels in quartile 4 were also associated with delirium severity by 1 week. At hospital discharge, interleukin-6, -8, and -10 retained the association but tumor necrosis factor-α, C-reactive protein, and S-100β lost their associations with delirium severity. Insulin-like growth factor-1 levels in quartile 4 were not associated with delirium severity at both time points. Interleukin-8 and S-100β levels in quartile 4 were also associated with higher in-hospital mortality. Interleukin-6 and -10, tumor necrosis factor-α, and insulin-like growth factor-1 were not found to be associated with in-hospital mortality.

CONCLUSIONS: Biomarkers of systemic inflammation and those for astrocyte and glial activation were associated with longer delirium duration, higher delirium severity, and in-hospital mortality. Utility of these biomarkers early in delirium onset to identify patients at a higher risk of severe and prolonged delirium, and delirium related complications during hospitalization needs to be explored in future studies.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Khan BA, Perkins AJ, Prasad NK, et al. Biomarkers of Delirium Duration and Delirium Severity in the ICU. Crit Care Med. 2020. PMID: 31770149. doi:10.1097/CCM.0000000000004139

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。